原发性胆汁性胆管炎的临床特征与治疗分层管理

陈瑜; 韩英

doi:10.3969/j.issn.1001-5256.2017.11.009

原发性胆汁性胆管炎的临床特征与治疗分层管理

DOI: 10.3969/j.issn.1001-5256.2017.11.009

陈瑜,
韩英

空军军医大学附属西京医院消化内科

详细信息

中图分类号: R575.22
计量
- 文章访问数: 2463
- HTML全文浏览量: 32
- PDF下载量: 667
- 被引次数: 0
出版历程
- 收稿日期: 2017-08-06
- 出版日期: 2017-11-20

Clinical features of primary biliary cholangitis and stratified treatment management

Chen Yu,
Han Ying

Department of Gastroenterology, Xijing Hospital Affiliated to the Fourth Military Medical University

摘要

摘要: 原发性胆汁性胆管炎(PBC)是一种异质性相对较强的疾病,不同患者的临床经过及表型可能存在较大差异。因此,必须给予长期的治疗和随访才能对患者进行准确的危险分层。通过观察PBC患者临床症状、检测指标的变化,对不同患者进行个体化的管理,才能使低风险的PBC患者得到规范化治疗,使高风险患者可能从各种精心设计的临床研究中获益。
- 胆管炎,胆汁性 /
- 临床方案 /
- 疾病管理
Abstract: Primary biliary cholangitis (PBC) is a disease with relatively strong heterogeneity, and different patients may have great differences in clinical process and phenotypes.Therefore, long-term treatment and follow-up are necessary for accurate risk stratification of these patients.Observation of clinical symptoms of PBC patients, measurement of the changes in related indices, and individualized management for each patient helps to provide standard treatment for low-risk PBC patients and bring benefits to high-risk patients through well-designed clinical studies.
- cholangitis, biliary /
- clinical protocols /
- disease management

HTML全文

参考文献(40)

[1]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.

[2]LINDOR KD, GERSHWIN ME, POUPON R, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.

[3]TRIVEDI PJ, LAMMERS WJ, van BUUREN HR, et al.Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis:a multicentre international study[J].Gut, 2016, 65 (2) :321-329.

[4]CARBONE M, MELLS GF, PELLS G, et al.Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J].Gastroenterology, 2013, 144 (3) :560-569.e7.

[5]CHEUNG A, LAMMERS WJ, HIRSCHFIELD GM, et al.Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis[J].J Hepatol, 2015, 62:s798.

[6]PRINCE M, CHETWYND A, NEWMAN W, et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years[J].Gastroenterology, 2002, 123 (4) :1044-1051.

[7]de LISO F, MATINATO C, RONCHI M, et al.The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA) -negative PBCpatients:a review of literature[J].Clin Chem Lab Med, 2017.[Epub ahead of print]

[8]LAMMERS WJ, van BUUREN HR, HIRSCHFIELD GM, et al.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study[J].Gastroenterology, 2014, 147:1338-1349.

[9] TRIVEDI PJ, BRUNS T, CHEUNG A, et al.Optimising risk stratification in primary biliary cirrhosis:AST/plateletratio index predicts outcome independent of ursodeoxycholic acid response[J].JHepatol, 2014, 60 (6) :1249-1258.

[10]NAKAMURA M, KONDO H, MORI T, et al.Anti-gp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J].Hepatology, 2007, 45 (1) :118-127.

[11]ZHANG LN, SHI TY, SHI XH, et al.Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis:results of a 14-year cohort study[J].Hepatology, 2013, 58 (1) :264-272.

[12]FLOREANI A, FRANCESCHET I, CAZZAGON N, et al.Extrahepatic autoimmune conditions associated with primary biliary cirrhosis[J].Clin Rev Allergy Immunol, 2015, 48 (2-3) :192-197.

[13]BOBERG KM, CHAPMAN RW, HIRSCHFIELD GM, et al.Overlap syndromes:the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J].J Hepatol, 2011, 54 (2) :374-385.

[14]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:the diagnosis and managementof patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.

[15]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.

[16]CARBONE M, SHARP SJ, FLACK S, et al.The UKPBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis[J].Hepatology, 2016, 63 (3) :930-950

[17]CORPECHOT C, ABENAVOLI L, RABAHI N, et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J].Hepatology, 2008, 48 (3) :871-877.

[18]PARES A, CABALLERIA L, RODES J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J].Gastroenterology, 2006, 130 (3) :715-720.

[19]CORPECHOT C, CHAZOUILLERES O, POUPON R.Early primary biliary cirrhosis:biochemical response to treatment and prediction of long-term outcome[J].J Hepatol, 2011, 55 (6) :1361-1367.

[20]KUMAGI T, GUINDI M, FISCHER SE, et al.Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J].Am J Gastroenterol, 2010, 105 (10) :2186-2194.

[21]TRIVEDI PJ, BRUNS T, CHEUNG A, et al.Optimising risk stratification in primary biliary cirrhosis:AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response[J].JHepatol, 2014, 60 (6) :1249-1258.

[22]HUET PM, VINCENT C, DESLAURIER J, et al.Portal hypertension and primary biliary cirrhosis:effect of long-term ursodeoxycholic acid treatment[J].Gastroenterology, 2008, 135 (50) :1552-1560.

[23]KAKUDA Y, HARADA K, SAWADA-KITAMURA S, et al.E-valuation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems[J].Hum Pathol, 2013, 44 (6) :1107-1117.

[24]WENDUM D, BOELLE PY, BEDOSSA P, et al.Primary biliary cirrhosis:proposal for a new simple histological scoring system[J].Liver Int, 2015, 35 (2) :652-659.

[25]CORPECHOT C, CARRAT F, POUJOL-ROBERT A, et al.Noninvasive elastography-based assessment ofliver fibrosis progression and prognosis in primary biliary cirrhosis[J].Hepatology, 2012, 56 (1) :198-208.

[26]FLOREANI A, CAZZAGON N, MARTINES D, et al.Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis[J].Dig Liver Dis, 2011, 43 (11) :887-892

[27]MAYO M, PARKES J, ADAMS-HUET B, et al.Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay[J].Hepatology, 2008, 48 (5) :1549-1557.

[28] NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.

[29]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.

[30]DHANDA A, LEE R, COLLINS P.Is primary biliary cirrhosis a steroid-sensitive autoimme disease?[J].Hepatol Res, 2012, 42 (6) :619-620.

[31]IWASAKI S, TSUDA K, UETA H, et al.Benzafibrate may have beneficial effect in pre-cirrhotic primary biliary cirrhosis[J].Hepatol Res, 1999, 16 (1) :12-18.

[32]RUDIC JS, POROPAT G, KRSTIC MN, et al.Bezafibrate for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2012, 1:cd450091.

[33]GRIGORIAN AY, MARDINI HE, CORPECHOT C, et al.Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:a meta-analysis[J].Clin Res Hepatol Gastroenterol, 2015, 39 (3) :296-306.

[34]PHILLIPS JR, ANGULO P, PETTERSON T, et al.Fat-soluble vitamin levels in patients with primary biliary cirrhosis[J].Am JGastroenterol, 2001, 96 (9) :2745-2750.

[35]MAILLETTE de BWL, BEUERS U.Bile salts and cholestasis[J].Dig Liver Dis, 2010, 42 (6) :409-418.

[36]TRIVEDI PJ, CORPECHOT C, PARES A, et al.Risk stratification in autoimmune cholestatic liver diseases:opportunities for clinicians and trialists[J].Hepatology, 2016, 63 (2) :644-659.

[37]ADAM R, KARAM V, DELVART V, et al.Evolution of indications and results of liver transplantation in Europe.A report from the European Liver Transplant Registry (ELTR) [J].J Hepatol, 2012, 57 (3) :675-688.

[38]GAUTAM M, CHERUVATTATH R, BALAN V.Recurrence of autoimmune liver disease after liver transplantation:a systematic review[J].Liver Transpl, 2006, 12 (12) :1813-1824.

[39]HUBSCHER SG, ELIAS E, BUCKELS JA, et al.Primary biliary cirrhosis.Histological evidence of disease recurrence after liver transplantation[J].J Hepatol, 1993, 18 (2) :173-184.

[40]BOSCH A, DUMORTIER J, MAUCORT-BOULCH D, et al.Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J].J Hepatol, 2015, 63 (6) :1449-1458.

施引文献

资源附件(0)

访问统计